University Cancer and Blood Center

Recent papers from University Cancer and Blood Center

1. Implementation of a clinical trial communication skills training workshop for oncology fellows: A mixed methods evaluationPEC Innovation · 2026
2. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk ModelJournal of Clinical Oncology · 2026
3. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN / HMAAmerican Journal of Hematology · 2026
4. ID #693 Medulloblastoma circulating tumor cell clusters are molecularly and functionally distinct from their corresponding primary brain tumor cellsNeuro-Oncology Pediatrics · 2026
5. Pre-transplant microRNA serum profiles and association with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantationFrontiers in Immunology · 2026
6. Favezelimab plus pembrolizumab for anti–PD-1–refractory classic Hodgkin lymphoma: an open-label phase 1/2 studyBlood Neoplasia · 2026
7. Enhancing recruitment of AYAs with Hodgkin lymphoma through community partnerships: Prioritizing diverse populations.Journal of Clinical Oncology · 2026
8. Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).Journal of Clinical Oncology · 2026
9. Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsHaematologica · 2026
10. Abstract LB009: Mapping the spatiotemporal dynamics of CD44v9 reveals a senescent cell therapy-resistant niche in pancreatic cancerCancer Research · 2026
11. Abstract LB017: Cluster of differentiation 44 variant isoform 9 defines cancer stem cell reservoirs in pancreatic intraepithelial neoplastic spatial nichesCancer Research · 2026
12. Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerJAMA Network Open · 2026
13. Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL StudyTransplantation and Cellular Therapy · 2026
14. 429P Real-world (RW) effectiveness and safety of lurbinectedin for previously treated small cell lung cancer (SCLC): Jazz EMERGE 402ESMO Open · 2026
15. Fertility Outcomes Following CAR T-cell Therapy: Results from a Patient-Facing SurveyTransplantation and Cellular Therapy · 2026
16. Blood cancer caregivers’ communication with clinicians about online cancer informationPalliative & Supportive Care · 2026
17. Characterizing open and avoidant communication in parents’ caregiving experiences of adolescents and young adults (AYAs) living with blood cancer: Linking communication and psychosocial outcomesPalliative & Supportive Care · 2026
18. Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregiversEpilepsy & Behavior · 2025
19. Brivaracetam effectiveness and patient-reported outcomes in clinical practice: Data from a 12-month prospective, observational study in the United StatesEpilepsy & Behavior · 2025
20. Safety, Tolerability, and Efficacy of Adjunctive Brivaracetam in Japanese and Chinese Patients with Focal-Onset Seizures: Interim Analysis of a Phase 3 Open-Label Extension TrialAdvances in Therapy · 2025